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Glioblastoma (GBM) is characterized by aberrant
vascularization and a complex tumor microenviron-
ment. The failure of anti-angiogenic therapies sug-
gests pathways of GBM neovascularization, possibly
attributable to glioblastoma stem cells (GSCs) and
their interplay with the tumor microenvironment. It
has been established that GSC-derived extracellular
vesicles (GSC-EVs) and their cargoes are proangio-
genic in vitro. To further elucidate EV-mediatedmech-
anisms of neovascularization in vitro, we perform
RNA-seq and DNA methylation profiling of human
brain endothelial cells exposed toGSC-EVs. To corre-
late these results to tumors in vivo, we perform histo-
epigenetic analysis of GBM molecular profiles in the
TCGA collection. Remarkably, GSC-EVs and normal
vascular growth factors stimulate highly distinct
gene regulatory responses that converge on angio-
genesis. The response to GSC-EVs shows a footprint
of post-transcriptional gene silencing by EV-derived
miRNAs. Our results provide insights into targetable
angiogenesis pathways in GBM and miRNA candi-
dates for liquid biopsy biomarkers.
INTRODUCTION
Glioblastoma (GBM), the most common primary brain cancer in
adults, is incurable, with 2- and 5-year survival rates of 16% and
5%, respectively (Ostrom et al., 2015). Aggressive diffuse
growth, high tumor heterogeneity, vascular abnormalities, andCell Re
This is an open access article under the CC BY-Na population of GBM stem-like cells (GSCs) are major factors
that complicate treatment (Ramirez et al., 2013; Harder et al.,
2018, Rooj et al., 2017; Garnier et al., 2019). Diffuse infiltrative
growth of GBM, which arises in large part due to the perivascular
migration of GSCs, precludes complete resection, sparing the
GSCs that resist chemotherapy and radiation and revive the tu-
mor (Hanif et al., 2017; Ramirez et al., 2013). The development of
effective targeted therapies is hindered by the heterogeneity and
plasticity of GBM cells, which provide the tumor with multiple
paths of resistance, while GBM vasculature provides various ob-
stacles to drug delivery (Ramirez et al., 2013; Zanders et al.,
2019; Perrin et al., 2019; Kane, 2019).
Extensive molecular profiling of GBM tissues (Freije et al.,
2004; Phillips et al., 2006; Verhaak et al., 2010), single cells (Patel
et al., 2014; Rooj et al., 2017; Neftel et al., 2019; Ricklefs et al.,
2016; Wang et al., 2019b), and secreted nanoparticles (Ricklefs
et al., 2016; Wei et al., 2017; Spinelli et al., 2018; Zhang et al.,
2019b) has driven recent developments in the identification of
GBM tumor subtypes that support a coherent model of GBM
heterogeneity. Gene expression-based tumor subtypes have
been resolved to sample-specific mixtures of up to 4 dominant
single-cell GBM expression signatures with unique underlying
functional cell states that are governed by genetic and microen-
vironmental cues, but appear to be both plastic and commut-
able, which is consistent with other similarities to neural
precursor cells (Neftel et al., 2019). Studies focused on GSCs
identified two distinct functional states that match GBM molec-
ular subtypes (Rooj et al., 2017; Wang et al., 2019b), as well as a
microRNA (miRNA)-driven, possibly extracellular vesicle (EV)-
mediated, bidirectional transition between distinct GSC sub-
populations within the tumor (Ricklefs et al., 2016; Rooj et al.,
2017). Molecular profiles of GSC-EVs suggest that their effects
within the tumor may depend on the molecular subtype andports 30, 2065–2074, February 18, 2020 ª 2020 The Authors. 2065
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
functional state of the donor cells (Spinelli et al., 2018; Wei et al.,
2017).
Heterotypic interactions of GSCs with immune, endothelial,
and other cells within the tumor microenvironment (TME) are
implicated in generating histological heterogeneity of GBM tu-
mors, recurrent treatment failures, and high lethality (Perrin
et al., 2019; Schiffer et al., 2018). Molecular profiles capturing
the effects of GBM on these non-malignant cells are emerging
(Sankowski et al., 2019; Venteicher et al., 2017), but the predom-
inant intercellular agents are not known. GSCs communicate
with the TME through several modes, including exchange of
soluble molecules and EVs, as well as by cell-to-cell contacts
(Broekman et al., 2018; Spinelli et al., 2019). The exchange of
molecules and genetic information via EVs plays a critical role
in GBM progression and tumor angiogenesis, which may involve
reprogramming the epigenome and transcriptome of endothelial
cells (ECs) (Aslan et al., 2019; Broekman et al., 2018; Godlewski
et al., 2017; Nakano et al., 2015; Quezada et al., 2018; Rooj et al.,
2016; Spinelli et al., 2018, 2019; Todorova et al., 2017; Treps
et al., 2017). An increasing body of evidence suggests a major
role for GSCs in non-conventional angiogenesis (Das and Mars-
den, 2013; Hardee and Zagzag, 2012; Kane, 2019), consistent
with the failure of anti-angiogenic drugs that typically target the
classic vascular endothelial growth factor (VEGF)-mediated
angiogenic pathways (Geraldo et al., 2019; Ameratunga et al.,
2018; Kane, 2019).
To further elucidate non-conventional angiogenic pathways
in GBM, we here examine the GSC-EV-mediated transfer of
extracellular RNAs (exRNAs) from human GSCs to human brain
microvascular ECs (HBMVECs) in vitro by molecular profiling
and to ECs in vivo via histoepigenetic analysis by computational
deconvolution. EV-derivedmiRNAsare known to convey growth-
promoting and angiogenic signaling in GBM (Beyer et al., 2017;
Chen et al., 2019; Todorova et al., 2017; Wong et al., 2015); how-
ever, the molecular events controlling this process in HBMVECs
are largely unknown. We hypothesized that GSC-derived ex-
RNAs, along with more conventional vascular GFs, jointly modu-
late thegene-expression landscapeofECs topromote angiogen-
esis. To this end, we compared the effects of GFs and GSC-EVs
on angiogenic pathways elicited in cultured HBMVECs, by asso-
ciating changes in DNAmethylome and total RNA profiles in ECs
with microRNA (miRNA) content of GSC-EVs. The expression
profiles obtained from ECs by histoepigenetic analysis of GBM
molecular profiles in the The Cancer Genome Atlas (TCGA)
collection (Cancer Genome Atlas Research Network, 2008) re-
vealed a concordance of effects in vitro and in vivo. Finally, we
identified candidate proangiogenic miRNAs that are transferred
via GSC-EVs into HBMVECs.
RESULTS
GFs and GSC-Derived EVs Induce Visually Similar
Vascularization Patterns but Divergent Transcriptional
and Epigenomic Changes in HBMVECs
To investigate the potential of GSC-EVs to elicit an angiogenic
response from brain microvasculature, we isolated EVs from
the conditioned media of GBM8 human primary GBM stem-
like cells (Wakimoto et al., 2012) and added them to the basal2066 Cell Reports 30, 2065–2074, February 18, 2020medium of HBMVECs cultured on a Matrigel substrate (Fig-
ure 1A, top panel). A standardized cocktail of angiogenic GFs
added to HBMVECs in identical conditions served as a positive
control. Cells cultured identically but without added stimulus
served as the baseline for comparison. Vascularization metrics
were quantified 16 h after application of the stimuli.
GSC-EV treatment (+EV) stimulated vascularization similar to
that of the GF treatment (+GF), as indicated by increases in total
tubule length and total counts of tubules, branch points, and
meshes (Figure 1A, bar plot). No meaningful vascularization
was observed when HBMVECs were treated with supernatant
from the EV isolation procedure (+GBM sup), nor with the
pellet or supernatant from amock isolation of EVs from uncondi-
tioned endothelial basal medium (+EBM pellet, +EBM sup) (Fig-
ure 1A, bar plot).
The responses obtained from GBM8-conditioned media
fractions (+EV,+GBMsup)andGFscouldnotbecomparedquan-
titatively because theconcentrations in theconditionedmedia are
not normalized to one another nor are they calibrated to physio-
logically relevant concentrations. These in vitro experiments
were designed to detect broad qualitative differences in the EC
response to EV and GF stimuli obtained according to well-estab-
lished (+EV; Zaborowski et al. 2015) or standardized (+GF; tube-
formation assay) protocols. Specifically, we asked whether the
similar vascularization phenotypes of +EV and +GF were associ-
ated with similar or divergent transcriptional and epigenomic
changes in HBMVECs. Over the set of synergic transcriptional
changes (>2-fold), we detected, for +EV and +GF, respectively,
the upregulation of 229 and 2 genes (Figure 1B, quadrant I, top
right) and the downregulation of 18 and 8 genes (Figure 1B, quad-
rant III, bottom left). Only 1 gene (SELE: E-Selectin) showed a
large concordant change (>2-fold decrease) in both treatments,
indicative of divergent transcriptional responses. We therefore
focused on the 78 genes showing opposite changes in transcript
levels, 72 of which showed larger perturbations in +EV as
compared to +GF (Figure 1B, quadrants II—top left and IV—bot-
tom right). Specifically, +EV decreased the abundance of 29
genes, with just 4 genes reduced by +GF. DNA methylation over
gene bodies and promoters also diverged (Figure 1C), with +GF
increasing and +EV decreasing on average, which is consistent
with the upregulation of more genes in +EV versus +GF. Methyl-
ation over 100-kb tiles taken genome-wide was less divergent,
with demethylation dominating for both treatments, although
the methylation gain was more pronounced with +GF, in accor-
dancewith the signal frompromoters andgenebodies. Thehighly
divergent transcriptomic and epigenomic responses to +GF
and +EV belie the similar vascularization phenotypes in vitro
and hint at different primary pathways of action.
Transcriptional and Epigenomic Perturbations Induced
by GFs and EVs In Vitro in HBMVECs Largely Resemble
Those within Human GBM Tumor ECs
To examine the relevance of our cell line experiments for
tumor biology in vivo, we compared the transcriptomic and epi-
genomic signatures observed in vitro to those observed in ECs
of human GBM tumors in vivo. Specifically, we exploited the
transcriptomic divergence to determine whether changes in
ECs in vivo correlated primarily with the in vitro responses of
Figure 1. GFs and GSC-Derived EVs Induce Similar Vascularization Patterns but Divergent Transcriptional and Epigenomic Responses in
HBMVECs
(A) Schematic and results of in vitro tube-formation assay. (i) Pellet and supernatant fractions were isolated frommedia conditioned by GBM8 neurospheres (EV,
GBM8 sup) or unconditioned media (EBM pellet, EBM sup). (ii) HBMVECs were cultured on Matrigel for 16 h under EBM containing angiogenic GFs or 1 of the 4
media fractions, then (iii) plates were photographed and harvested for molecular profiling. (iv) Bar plot shows tube-formation assay (n = 4) metrics (mean ± 95%
confidence interval [CI]).
(B) Comparative transcript-level changes for +GF versus +EV (log2 fold change versus ‘‘EBM only’’; n = 2) (quadrant I is top right and that quadrant numbering is
counterclockwise).
(C) Comparative DNA methylation changes (log2 fold change versus EBM only; n = 3).HBMVECs to +GF or +EV. GBM-associated changes in ECs
in vivo were identified by the histoepigenetic analysis of glioma
tumors from the TCGA collection (Brennan et al., 2013) using
the Epigenomic Deconvolution (EDec) method (Onuchic et al.,
2016). The TCGA GBM collection generally lacks molecular
profiling data for matched normal non-cancerous samples, so
we included lower-grade glioma (LGG) samples as a control
group, given that microvascular structures of GBM and LGG
are characteristically disparate (Guarnaccia et al., 2018; Louis
et al., 2007; Bergers and Benjamin, 2003).
EDec estimated 5 cancer-cell epigenome profiles, all of
which correspond to previously defined LGG and GBMmolecu-
lar subtypes. In GBM tumors, 3 of the cancer-cell profiles
(GBM 1, 2, and 3) were found in appropriately high proportionswithin tumors of the Proneural+G-CIMP (glioma-CpG island
methylator phenotype), classical, and proneural subtypes
(Figure 2A). The remaining profiles (LGG1 and LGG2) were en-
riched within LGG tumors (Figure 2A). EDec also estimated
proportions of 4 non-cancer cell types: neuronal, glial, immune,
and endothelial. Normal adjacent tissue samples collected by
TCGA were highly enriched for non-cancer profiles, although
some cancer profiles could be detected in certain samples,
consistent with the diffuse growth of gliomas (Figure 2A).
The GBM8 epigenome revealed the greatest similarity to that
of the estimated Proneural cancer epigenome (Figure 2B,
GBM.3), consistent with the previous characterization of
the GBM8 cell line as a Proneural-like, stem-like cell type
with wild-type IDH1 (Teng et al., 2017). The results indicateCell Reports 30, 2065–2074, February 18, 2020 2067
Figure 2. Transcriptional and Epigenomic Perturbations Induced In Vitro by GFs or GSC-Derived EVs in ECs Largely Resemble Those within
Human GBM Tumors
Histoepigenetic analysis of GBM and LGG tumors in the TCGA collection identified constituent cell types of in vivo GBM and LGG tumors (cancer, endothelial,
immune, glial, and neuronal).
(A) Inferred cellular composition of GBM tumors (classical, mesenchymal, and proneural ± G-CIMP) and LGG tumors (astrocytoma, oligoastrocytoma, oligo-
dendroglioma). The inferred cancer epigenomic profiles (LGG1 and -2 and GBM1, -2, and -3) are enriched in specific tumor subtypes. Non-cancer epigenomic
profiles are named according to the highest correlation with normal reference profiles and expression of select marker genes.
(B) Correlation of deconvoluted profiles with GBM8 GSCs is consistent with the proneural origin of GBM8 (see A, GBM.3 profile).
(C) Intersection of expression changes of the EC fraction in vivo (GBM versus LGG) and in vitro (+GF or +EV versus EBM). Quadrants II and IV show genes with
opposite changes in HBMVECs upon +GF and +EV treatments (color denotes treatment-specific concordance with the expression change in vivo; this panel
shows a subset of genes from Figure 1B) (quadrant I is top right and that quadrant numbering is counterclockwise).
(D) Side-by-side view of in vivo and in vitro DNA methylation changes (this panel includes the data from Figure 1C, augmented by in vivo changes).successful deconvolution, warrant confidence in the inferred
gene expression profiles, and validate the GBM8 cell line as an
in vitro model for GBM in the TCGA collection. The differences
in deconvoluted EC gene expression and methylation profiles
between GBM and LGG should therefore reflect GBM-associ-
ated differences of the microvasculature in vivo. Differential2068 Cell Reports 30, 2065–2074, February 18, 2020expression analysis of GBM versus LGG ECs revealed GBM-
associated perturbations (>2-fold change, false discovery rate
[FDR] < 0.05) of 1,632 genes.
To determine whether GFs or EVs play a dominant role
in vivo, we asked whether the GBM-associated transcriptomic
perturbations in vivomostly reflected the transcriptomic response
ofHBMVECs to+GFor+EV in vitro (Figure 2C). The treatments eli-
cited divergently trending changes from 597 (42+243)+(284+28)
of the 1,632 genes (Figure 2C, quadrants II—top left and IV—bot-
tomright), and thedirectionsof+GF-inducedexpressionchanges
were concordant with 54.6% [(42 + 284)/597] (p = 0.0023, bino-
mial test) of the GBM-associated perturbations (Figure 2C,
orange dots). This suggests a somewhat larger transcriptional
influence of GF compared to GSC-EV stimulation in vivo. More-
over, DNA methylation differences of GBM ECs in vivo were
overwhelmingly more concordant with those observed in
HBMVECs upon +GF treatment, especially over gene body and
promoter regions (Figure 2D). These observations are consistent
with a highly dominant effect of GFs on transcriptional regulation,
leaving open the possibility of post-transcriptional influence of
GSC-EVs, perhaps mediated by miRNAs.
Transcriptional Perturbations of Angiogenic Pathways
in ECs Are Consistent with Post-transcriptional
Silencing by GBM EV miRNAs Transferred into ECs
To explore the possibility that miRNAs delivered to ECs by
GSC-EVs contribute to post-transcriptional downregulation,
we focused on the 28 genes downregulated in vivo and
in vitro by +EV only (Figure 2C, quadrant IV—bottom right
blue dots). Asking whether the magnitude of changes in vitro
correlate with those observed in vivo, we observed significant
correlation (R = 0.57), supporting a gene-silencing role for
GSC-EVs in vivo (Figure 3A). To explore this more broadly,
we exploited the fact that transcriptionally modulated attenua-
tion should leave ‘‘epigenomic footprints’’ at gene-regulatory
regions, whereas most gene attenuation by miRNAs would
be post-transcriptional and leave no such signature. Joint ex-
amination of transcriptomic and DNA methylation changes at
genes with detectably altered promoter DNA methylation re-
vealed that diminished expression was accompanied by
increased promoter methylation with +GF (p = 1.77 3 105,
chi-square test), as expected for transcriptionally mediated
gene silencing (Figure 3B), whereas decreased expression
did not accompany promoter methylation gain with +EV (p =
0.26, chi-square test) (Figure 3C), which is consistent with
post-transcriptional regulation by miRNAs.
This prompted us to ask which miRNAs may be delivered by
GSC-EVs to effect gene attenuation in HBMVECs. Small RNA
sequencing (RNA-seq) of HBMVECs before and 16 h after +EV
treatment revealed an increased abundance of 8 miRNAs
(Figure 3D, upper right), consistent with the uptake of GSC-EV
miRNAs. To determine the potential for EV-mediated delivery
of these 8 miRNAs to HBMVECs, we analyzed small RNA-seq
data from GSC-EVs of 4 GBM cell lines (20/3, GBM8, GBM4,
and MGG75; Wei et al., 2017). The ubiquitous presence of the
8 miRNAs in GSC-EVs (Figure 3D, right panel) substantiates
the inference that the miRNAs were not simply transcribed in
HBMVECs as an effect of +EV treatment. Relative to all of the
other miRNAs identified within GBM8 EVs, 3 of the 8 miRNAs—
hsa-miR-9-5p, hsa-miR-22-3p, and hsa-miR-182-5p—were
significantly enriched (Figure 3D, right panel). Similarly, GBM4
and MGG75 EVs were enriched in 4 and 5, respectively, of the
candidate miRNAs, with both lines also showing strong enrich-
ment for miR-9-5p.We then asked whether some of the 8 miRNAs were associ-
ated with the downregulation of validated miRTarbase (Chou
et al., 2018) target mRNAs in vitro (HBMVEC, +EV) or in vivo
(GBM ECs). The strongest and the only statistically significant
signal was obtained for hsa-miR-9-5p, with the following 3
target genes downregulated both in vitro and in vivo: RGS5,
ABCB1, and SOX7 (Figure 3E, right panel, bottom).
We next tested the 28 genes (downregulated in vivo and
in vitro by +EV only) for association with angiogenesis pathways
(Figure 3E, right panel). Gene set enrichment analysis (GSEA)
identified significant enrichment in 4 angiogenesis-related
pathways. A comparable 5 angiogenesis pathways were re-
turned when we queried the 284 genes upregulated in vivo
and specifically in response to +GF treatment. In contrast, no
angiogenesis pathways were enriched in the 42 genes uniquely
downregulated in response to +GF treatment. These results
suggest that the downregulation of angiostatic genes, which
could be mediated by miRNAs, may be a unique feature of
GSC-EV communication.
miR-9-5p in GBM Stem Cells Supports Metabolic
Activity and May Influence Resistance to Therapeutic
Intervention on LGGs
The signature associated with miR-9-5p is consistent with
proangiogenic influence; therefore, we aimed to assess the de-
gree to which it contributes to the pro-angiogenic effect of
GSC-EVs. Therefore, we aimed to treat HBMVECs with EVs
derived from GBM8 cells depleted of miR-9-5p. However,
knockdown of miR-9-5p severely reduced the metabolic
activity of the GBM8 neurosphere cultures as measured by
the WST assay (Figures 4A and 4B), ending this line of investiga-
tion. This result suggested the possibility that the effects of
the export of miR-9-5p from cancer cells may play a distinct
and complementary role to its angiogenic effects in ECs.
To identify other GSC-EV miRNAs that may drive vascular
proliferation, we aimed to contrast miRNA compositions of
LGG-derived EVs (LGG-EVs) and GSC-EVs hypothesizing
that LGG-EVs would be less angiogenic and that comparison
of miRNA compositions would highlight additional pro-angio-
genic GSC-EV miRNAs. Due to constraints associated with
the culture of LGG cell lines, we could not isolate enough LGG
EVs for analysis. We therefore sought to use histoepigenetic
analysis to facilitate comparison of the miRNA composition
of ECs and cancer cells in LGG versus GBM as a proxy for
direct investigation of miRNA levels in the respective isolated
EVs. Unavailability of small RNA-seq expression data for
GBM in the TCGA collection precluded this analysis. Small
RNA-seq data are, however, available for the LGG samples.
Thus, we performed additional histoepigenetic analysis to
compare the in vivo expression patterns of miRNAs in the
cancer and EC fractions of LGG tumors under the premise that
therapy-resistant LGG may contain a significant undetected
proportion of GSCs cells that survive treatment. We focused
on LGG samples with a component of astrocytic neoplasia
and grouped them by response to therapeutic intervention
(progression or remission) and tumor molecular subtype (astro-
cytoma, oligoastrocytoma) for the analysis. We did not detect
meaningful differences in the ECs or GSC-like cells based onCell Reports 30, 2065–2074, February 18, 2020 2069
Figure 3. Identification of Candidate miRNAs that May Mediate EV-Induced Vascularization
(A) The 28 genes downregulated in vitro upon +EV treatment (indicated by blue dots in E, quadrant IV) show concordant downregulation in vivo with correlated
magnitudes (R = 0.57).
(B and C) Transcript depletion upon +GF treatment associates with DNA methylation gain over promoters (B), whereas transcript depletion upon +EV treatment
does not associate with promoter methylation (C).
(D) Of the miRNAs that showed a notable increase in abundance in HBMVECs following +EV treatment (top 8 rows of heatmap, first column of table), 5 showed
significantly high abundance within GSC-EVs (center columns of table, highlighted in gray). Downstream targets of miR-9 were significantly downregulated (last
column of table).
(E) GSEA implicates 5 angiogenic pathways enriched for the 284 genes upregulated in vivo and upon +GF treatment (quadrant IV, orange dots) and 4 angiogenic
pathways enriched for the 28 genes downregulated in vivo and upon EV treatment (quadrant IV, blue dots) (quadrant I is top right and that quadrant numbering is
counterclockwise).
2070 Cell Reports 30, 2065–2074, February 18, 2020
Figure 4. miR-9-5p Supports theMetabolic Activity of GBMStemCells andMay Influence Resistance to Therapeutic Intervention onGliomas
(A) GBM8 neurosphere cultures: transfected with 50 nM lipofectamine plus no oligonucleotide (i, mock); FAM-labeled scrambled oligonucleotide (ii, v, scram-
bled); or FAM-labeled antagomir (iii, vi, miR-9-5p antisense); non-transfected GBM8 (iv). Micrographs taken 12 days after transfection (seeding at 13 104 cells/
well). Scale bar, 200 mm.
(B) Metabolic activity (mean ± SD) of transfected cells measured by WST-1reduction assay.
(C) miR-9-5p levels (mean ± SD) in the cancer cell fraction of LGG tumors (astrocytomas or oligoastrocytomas), stratified by response to therapeutic intervention.this stratification, but we did observe that treatment-resistant
LGG tumors tended to have lower miR-9-5p levels in the GSC-
like fraction (Figure 4C), consistent with cancer resistance
induced by the export of miR-9-5p from cancer cells.
DISCUSSION
We provide multiple lines of evidence from both in vitro
experiments on cell lines and computational deconvolution of
tumors in vivo that EV-mediated transfer of RNAs from GBM
cells to brain ECs induces angiogenesis. Similar morphologic
patterns of vascularization induced by in vitro treatment of
HBMVECs with either GFs or GSC-EV stand in sharp contrast
to highly divergent transcriptional and epigenomic changes
observed in HBMVECs upon these 2 treatments. While the
angiogenic pathway response to GFs is characherized by
gene upregulation, downregulation dominates the angiogenic
pathway response toGSC-EVs.Moreover, 28 of 29 genes down-
regulated by GSC-EVs in vitro were also downregulated in vivo
without observable gains in promoter methylation, which is
consistent with post-transcriptional downregulation by miRNAs
delivered from GSCs to ECs.
Following up on the above results, we identified 8 candidate
miRNAs that may mediate the EV-associated angiogenesis.
The set includes miR-148a and miR-9-5p, both previously asso-
ciated with glioma angiogenesis (Kim et al., 2014; Zhang et al.,
2019a; Madelaine et al., 2017; Yi and Gao, 2019) and poor sur-
vival. Our results are concordant with previous studies (Chen
et al., 2019) reporting that whenmiR-9 is delivered to human um-
bilical ECs (HUVEC) via GBM-derived EVs, its expression levels
in HUVECs directly correlated with the resulting tubule formation
count and length. Our results are also concordant with previous
studies (Wong et al., 2015) reporting that the silencing of miR-
148a normalizes the aberrant tumor vasculature in mouse
models of GBM.In search of downstream mediators of angiogenesis, we also
examined transcript-level changes of validated mRNA targets
of miR-9 (Chen et al., 2019). Three miR-9 targets (RGS5,
SOX7, and ABCB1) were downregulated both in vivo in GBM
ECs and in HBMVECs by GBM8-EV treatment in vitro. RGS5
plays a central role in vascular growth (Svensson et al., 2015);
it has been shown to reduce endothelial growth (Wang et al.,
2019a); and small interfering RNA (siRNA)-mediated knockdown
of RGS5 stimulates endothelial growth (Jin et al., 2009). In a wide
variety of cell types, both tumor and normal, SOX7 inhibits cell
proliferation by antagonizing the Wnt/b-catenin signaling
pathway, whereas miRNA-mediated knockdown of SOX7 re-
stores proliferation (Zheng et al., 2016). SOX7 expression is crit-
ical for physiological angiogenesis, and its loss leads to weakly
formed microvasculature (Kim et al. 2016).
Our results raise the possibility that miRNA export may also
have important consequences for cancer cells. Specifically,
xenobiotic efflux pumps such as ABCB1 appear to play roles in
cancer therapy resistance. Speculatively, the depletion of miR-
9-5p inglioblastomacellsmayweaken theefficacyof chemother-
apeutics such as temozolomide by de-repression of ABCB1, a
miR-9 target, and consequent improvement of drug efflux. In
that regard, we note that the overexpression of ABCG2, another
xenobiotic efflux pump and target ofmiR-16-2-3p (found inGSC-
EVs) can result in temozolomide resistance and poor clinical out-
comes (Emery et al., 2017; de Gooijer et al., 2018). Moreover,
reduction of the metabolic activity of GBM8 GSCs induced by
the knockdown of miR-9-5p is consistent with previous reports
of decreased proliferation in other GBM cell lines (Chen et al.
2019), suggesting that removal of miR-9-5p may also confer
chemotherapy resistance by reducing proliferation.
The diversity of secreted nanoparticles that carry exRNA
and the heterogeneity of many nanoparticle isolates are increas-
ingly recognized sources of confounding in exRNA studies and
thus require careful consideration. Recent reports highlightCell Reports 30, 2065–2074, February 18, 2020 2071
distinct nucleic acid compositions of vesicular and non-vesicular
carriers of exRNA (Wei et al., 2017; Jeppesen et al., 2019), while
others demonstrate that common EV isolation protocols often
co-isolate non-vesicular carriers (Jeppesen et al., 2019; Murillo
et al., 2019). Thus, clear evidence obtained using improved
isolation methods is required before attributing RNA transfer to
a specific carrier class. In that regard, the stringent studies by
Wei et al. (2017) and Jeppesen et al. (2019) identified miR-9-5p
as enriched in the vesicular fractions of 4 distinct GBM
cell lines (GBM8, GBM4, MGG75, and Gli36), suggesting that
miR-9-5p is a bona fide EV-derived miRNA in these systems.
Jeppesen et al. (2019) reported enrichment of miR-22 miR-
148a-3p, and miR-182-5p in the non-vesicular fraction of
Gli36 (an established glioma cell line), although they were identi-
fied as enriched in EVs by Wei et al., 2017 in primary GBM
GSC cultures. Because our EV isolation method was less strin-
gent, we cannot completely rule out the effects of co-isolated
non-vesicular miRNA on angiogenesis in our system.
While there are manifold mechanisms by which the tran-
scriptome can be modified, the present analysis accounts
only for variations in the transcript levels of miRNAs and
messenger RNA (mRNA) resolved at the level of genes. Our
study does not address subtler transcriptomic changes,
including alternative transcript initiation, alternative splicing,
or post-transcriptional nucleobase modifications, nor does it
consider non-coding RNAs other than miRNAs. It will be of in-
terest to determine in future studies whether the EV-mediated
changes involve a greater degree of post-transcriptional mod-
ifications and whether exRNAs other than miRNAs may be
involved as mediators.
The implied role of EV-miRNAs in GBM vascularization re-
vealed in this study has both therapeutic and diagnostic implica-
tions. EV and GF signaling likely exhibits spatial and temporal
heterogeneity within a tumor, and their relative contributions
could account for substantive and clinically important differ-
ences in the types of vessels formed—for example, with respect
to permeability and morphology. Because of the poor accessi-
bility of brain tumors, liquid biopsy biomarkers that may distin-
guish highly malignant GBM from LGG have potentially
high clinical utility. In that regard, previous studies detected
GBM-associated EVs in patient plasma (Jones et al., 2019),
elevated levels of miR-9 in GBM tissues (Wu et al., 2013) and
in the serum-derived EVs (Ji et al. 2016) and cerebrospinal
fluid (CSF) (Sørensen et al. 2017) of acute ischemic stroke pa-
tients, suggesting miR-9 as a potential liquid biopsy marker for
GBM progression and brain damage. The prognostic value of
miR-9 levels has already been endorsed with its inclusion in
multi-marker prognostic panels for GBM (Yuan et al., 2017).
Our study supports these results by providing a mechanistic
role of miR-9 in GBM progression. By elucidating pathways of
GBM vascularization that are distinct from the well-known GF
pathway, our results open the way toward new types of anti-
angiogenic therapies of these lethal tumors.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture
Established primary human glioblastoma cells (GBM8 (also called MGG8), kindly provided by H. Wakimoto through A. Krichevsky,
Harvard Medical School, Boston, MA) were cultured as spheroids in 0.22um-filtered Neurobasal medium (GIBCO Invitrogen Cor-
poration, San Diego, CA) supplemented with Glutamax (GIBCO Invitrogen Corporation, San Diego, CA) (3mM), N2 (GIBCO Invitrogen
Corporation, San Diego, CA) (0.5mL/100mL), B27 (GIBCO Invitrogen Corporation, San Diego, CA) (2mL/100mL), EGF (R&D system)
(20ng/mL), FGF (PEPROTECH) (20ng/mL), and penicillin-streptomycin (10 IU/mL and 10 mg/mL, respectively, Sigma-Aldrich, St
Louis, MO, USA). GBM8 were used at passages 23 to 25. Primary Human Brain Microvascular Endothelial Cells (HBMVEC) from
Cell Systems (Catalogue #ACBRI-376, Kirkland, WA, USA) were cultured in EGM-2 MV (Lonza, Basel, Switzerland) supplemented
with 5% EV-depleted FBS. FBS was depleted from EVs by 16 h of ultracentrifugation at 160,000 x g. Cells were maintained at
37C in a humidified atmosphere with 5% CO2. HBMVECs were used at passages 5-8. Growth medium (EBM-2) from plates where
no cells were seeded (unconditioned medium – UCM) was included in the experiments and used as a negative control. Cells were
regularly checked formycoplasma contamination usingMycoplasma PCRdetection kit (ABM, Richmond, BC) and only negative cells
were used for the experiments. In brief, conditioned media (cultured for at least 24 hours) was collected, centrifuged at 2,000 x g to
get rid of cell debris and subjected for PCR. HBMVECs andGBM8 cells were confirmed to be female (by analysis of sex chromosome
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Extracellular Vesicle Purification
GBM8 single cells were seeded at 10,000 cells/cm2 in four 150mm dishes and cultured as neurospheres for 8 days, adding fresh
medium every 3 days. GBM8 neurospheres were then transferred on basal medium (EBM-2 Basal Medium, Lonza, Basel,
Switzerland) for 48 hours before extracellular vesicle (EV) isolation.
The conditioned basal medium (100mL) from approximately 20million GBM8 cells was harvested after 48 hr. The EVswere isolated
by differential centrifugation. Briefly, conditioned and unconditioned media were centrifuged at 3003 g for 10 min at 4C to remove
any cells/cell debris. The supernatant was transferred to a clean 50mL tube and further centrifuged at 2,0003 g for 10minutes at 4C
to remove additional cell debris. The supernatant was then transferred to a clean ultracentrifuge tube (Beckman Coulter, Brea, CA,
USA) and ultracentrifuged at 100,000 3 g for 90 min at 4C (70.Ti Beckman rotor) to obtain EV-enriched pellet. The ultracentrifuged
conditioned and unconditioned supernatants were removed and preserved at 4C and the EV pellets and the UCM pellets were
resuspended in 200uL of sterile double-filtered (df) (0.22um) PBS. EV pellets were measured for their nanoparticles content
using Nanosight instrument technology (NanoSight NTA 2.2 software) (3x60sec videos/sample, detection threshold: 6). All of the
EV pellet isolated from the three independent experiments were used to treat the HBMVEC cells. In parallel, we collected EV pellets
from approximately 20 million GBM8 cells, and the purified EVs were characterized using NTA.
HBMVEC in vitro Angiogenesis Assay
HBMVECs (500,000/well) were cultured on Matrigel-coated (BD Matrigel 10mg/mL, BD Biosciences, Franklin Lakes, NJ, USA) wells
in a 6-well plate in i) endothelial basal medium (EBM-2); ii) EBM-2 supplemented with a cocktail of angiogenic factors (EGM-2 Single-
Quot Kit Suppl. & Growth Factors, Lonza); iii) EBM-2 with 200 ul GBM8-derived EV pellet (10x104EVs/cell); iv) EBM-2 with 200 ul
GBM8-derived supernatant; v) EBM-2 with 200 ul UCM-derived pellet; and vi) EBM-2 with 200 ul UCM-derived supernatant. After
16 hours of exposure, 3 random pictures at 4X and 25 random pictures at 10X per well were taken. Angiogenesis was analyzed
with the ImageJ software (NIH). Specifically, the tubules length (10X), the number of tubules (10X), the number of branching points
(10X), and the mesh size (4X) were assessed. Experiments were conducted in triplicates.
Cell culture and transfection for RNA inhibition
Confluent GBM8 cells were dissociated into single cell suspension using the Neurocult Stem Cells chemical dissociation kit (Stem
Cell Technologies). The cells were transfected via magnetofection with magnetic nanobeads (Neuromag, Oz Biosciences) either with
fluorescently-labeled miRCURY LNATM hsa-miR-9-5p inhibitor or scramble control at a final concentration of 50 nM. The mixture of
transfection reagent and miRNA inhibitor was added directly to cells and seeded into 6-well plate at density of 1x104 cells/well.
Growth of GBM8 neurospheres was monitored up to 12 days in vitro.
WST-1 Assay for Cell Proliferation and Viability
Cell viability was assessed byWST reduction assay (Cell counting kit, Dojindo), which detects dehydrogenase activity of viable cells.
The cells were incubated with 10% WST reagent for 2 hours at 37C. The absorbance of the culture medium was measured with a
microplate reader at a test and reference wavelengths of 450 nm and 630 nm respectively. The cell viability was calculated as a
comparison to the control/mock group (only transfection agent, no miRNA inhibitor). Data are represented as mean + SEM of 3 in-
dependent experiments. Statistical significance was evaluated using one-way ANOVA to compare among groups, with Tukey’s test
for multiple comparisons. A p value of < 0.05 was considered to be statistically significant.
METHOD DETAILS
Total genomic DNA and RNA extraction
After 16 hours of exposure, the medium was gently removed, centrifuged at 2,000 x g for 15 minutes at 4C to collect floating cells,
and dry pellets preserved at 4C. Equilibrated (37C) Dispase (BD Biosciences, Franklin Lakes, NJ, USA) was added (0.2 mL per cm2)
to Matrigel and incubated at 37C for 1.5 h. After pipetting to carefully resuspend the cells, 3.6 mL EDTA (5mM sterile, pH = 8) was
used to stop Dispase activity and cells were pelleted twice by centrifugation (2,000 x g for 15 minutes at 4C). Cell pellets from
medium andMatrigel were collected for each sample andwashed in 600 ul sterile dfPBS (1X PBS, filtered through 0.22 um filter twice)
at 2,000 x g for 15 minutes at 4C and finally resuspended in 100 ul sterile dfPBS for either DNA or RNA extraction.
Selection of RNA isolation methods can greatly impact exosomal RNA yield and size distribution, and ultimately data interpretation
(Eldh et al., 2012; Srinivasan et al., 2019). Total RNA for this study was isolated from samples using the QIAGEN (Exiqon) miRCURY
RNA isolation kit. The miRCURY kit was chosen since it was one of the best performing kits in terms of cellular and exosomal RNA
yield and size distribution (Eldh et al., 2012; Srinivasan et al., 2019).
Genomic DNAs for methylation analysis were purified (QIAGEN QIAamp DNA Micro Kit, QIAGEN,Stanford, CA, USA) from
HBMVECs cultures as above, and also from GBM8 cells cultured (in triplicate) for 48h both in supplemented Neurobasal medium
(GIBCO Invitrogen Corporation, San Diego, CA) and in basal medium (EBM-2 Basal Medium, Lonza Biologics Inc., Portsmouth,
NH, USA).e2 Cell Reports 30, 2065–2074.e1–e4, February 18, 2020
RNA isolation and Sequencing
Long RNA sequencing
RNA-sequencing was performed using the Clontech/Takara SMARTer Stranded Total RNA-seq PICO v2 kit (Clontech/Takara
634414) for long RNA expression profiling. All libraries then had 75 bp paired end sequencing on the NextSeq500 using a 150 cycle
high output kit. Raw Illumina readswere quality filtered as follows. First, ends of the readswere trimmed to removeN’s and baseswith
quality less than 20. After that the quality scores of the remaining bases were sorted and the quality at the 20th percentile was
computed. If the quality at the 20th percentile was less than 15, the whole read was discarded. Also, reads shorter than 40 bases
after trimming were discarded. If at least one of the reads in the pair failed the quality check and had to be discarded, we discarded
the mate as well.
Transcript Abundance and Differential Expression Estimates for long RNA
Prior to mapping for transcript-level quantification, to assess sample integrity all fastq files from long-RNA sequencing runs were
uploaded to the Genboree workbench and mapped to hg19 and all exogenous genomes using the exceRpt [v4.6.3] small RNA-
seq pipeline (Kaczor-Urbanowicz et al., 2018; Rozowsky et al., 2019). Data quality assessment and read clipping was performed us-
ing TrimGalore [v0.4.1] with CutAdapt [v1.15] and FastQC[v0.11.6] (Martin, 2011). Paired-reads were mapped simultaneously to the
GRCh37.83 cDNA and ncRNA transcriptomes (Kinsella et al., 2011) using Kallisto [v0.44.0] (Bray et al., 2016). Kallistos were imported
to R with tximport. All reads mapping to ncRNA were excluded from the analysis, then transcript abundances were aggregated by
Ensembl Gene ID. Genes with less than 10 reads across all samples were excluded from further analysis. Differential transcript
abundance was characterized by DeSeq2 with EBM as the baseline for all treatments, and samples treated as paired within repli-
cates. Threshold values for differential expression were set at 2 and 0.05, respectively, for fold change and adjusted p value.
Small RNaseq Library Preparation and Sequencing
Small RNaseq libraries were generated using the NEB Next SmallRNA library preparation kit according to the manufacturer’s
protocol, with some minor modifications. The reaction volumes were reduced to 1/5thof the recommended volume. Due to the
low amounts of RNA input, the 30 SR adaptor, SR RT primer and the 50 SR adaptors were diluted 1:6 to avoid excessive amounts
of free adaptors and the formation of adaptor dimers. The final libraries were purified using the Zymo DNA clean and concen-
trator-5 kit and subjected to size selection on the Pippin Prep with a cut off between 117 and 135 bp to deplete adaptor dimers
and most of larger RNA species such as tRNA fragments. The size selected libraries were then sequenced on a HiSeq 4000
sequencing system.
Small RNaseq Data Analysis
Condition2 Replicate1 was removed from analysis due to a markedly lower total miRNA count (273,468) compared to the other 8
samples (nearly 5x fewer counts than the sample with the next fewest counts). In the remaining samples, the samples with the fewest
total miRNA counts (which was Condition3 Replicate2) had a total miRNA count of 1,338,649. Therefore, the scaled data for the re-
maining samples were filtered to remove miRNAs with fewer than 7.5 scaled counts (corresponding to a cutoff of 10 raw counts/
1,338,649 total miRNA counts) in at least 2 samples; after this filtering, 430 miRNAs remained. The data were further filtered using
the Qlucore data analysis and visualization software package (https://www.qlucore.com) by selecting for miRNAs that displayed
a variance across the dataset of 0.01, leaving 29 miRNAs. Differential expression analysis was then performed among the three
conditions, and using a p value < 0.03/q-value < 0.75, obtained 15 miRNAs.
QUANTIFICATION AND STATISTICAL ANALYSIS
Methylation analysis
HBMVECs and GBM8 genomic DNA 3-replicates for each sample were submitted for genomic methylation analysis to the Transla-
tional Genomics Core (65 Landsdowne Street, Cambridge,MA 02139). Methylation analysis on genomic DNAswere performed using
the Illumina Human 450K Infinium Methylation BeadChip.
(https://personalizedmedicine.partners.org/Translational-Genomics-Core/Services/Genotyping/Methylation.aspx)
Differential Methylation Analysis
Illumina Human 450K Infinium Methylation BeadChip beta values were input to RnBeads [version 2.0.1] with annotations from
RnBeads.hg19 [version 1.14.0] (Assenov et al., 2014) in R [version 3.5.1]. Filtering removed probes annotated as non-CpG, cross-
reactive, snp-containing, or on sex chromosomes. Probes with variance of less than 0.05 across all samples were excluded. All com-
parisonswere performedwith EBMas the baseline. Differential methylation was determined over annotated gene body and promoter
regions using limma.
Statistics
The statistical analyses for angiogenesis assay were performed using GraphPad software 6.0 (GraphPad software Inc., La Jolla, CA
92037 USA). Shapiro’s test was performed to check for normality. Either t test or Mann-Whitney were applied to analyze the in vivo
angiogenesis assay. P threshold of significance was fixed as p < 0.05.Cell Reports 30, 2065–2074.e1–e4, February 18, 2020 e3
GSEA
Pathways analysis was performed using Gene Set Enrichment Analysis. The pathways were collated by running the candidate genes
using the ‘‘Compute Overlap’’ feature. All presented pathways have FDR < 0.05.
Epigenomic Deconvolution
EDec R script (Onuchic et al., 2016) was utilized to deconvolute the GBM, LGG, and normal samples collected by TCGA. Following
the EDec instructions, Stage 0 informative probes were collected by running a t test across the 450K array beta values of cell type
references collected from GEO database. This included GBM8 cell lines, glia, neurons, immune, and endothelial cell profiles. For
Stage 1, k = 9 was selected as the most stable model using the estimate stability function which uses 80% of the data over n = 3
iterations. Stage 1 results in the deconvoluted methylation profiles and per-sample proportions (Figure 2A). Each profile was corre-
lated to the GEO references across the informative probes to determine its identity by selecting the highest correlation. Stage 2
was performed on GBM and LGG sample separately to determine the endothelial cell type specific gene-expression. Differential
expression was calculated using the mean, standard errors and degrees of freedom calculated by EDec Stage 2. All reported
changes are > 2 fold-change and FDR < 0.05.
DATA AND CODE AVAILABILITY
The RNA-seq and DNA-methylation data produced in the course of this study are accessible via GEO archives at the NCBI accession
GEO: GSE138115.e4 Cell Reports 30, 2065–2074.e1–e4, February 18, 2020
